

Introduction:

The 41st Annual Scientific Meeting of the British Society of Toxicologic Pathology is taking place on the 19th – 20th November 2026 at the Hilton Hotel, Cambridge, UK and is held in conjunction with The Pathological Society of Great Britain and Ireland. The topic is “Of Mice and Men: Synergy Between Veterinary and Human Pathology.” This meeting will cover a broad range of translational topics including pathology and modelling of MASLD and kidney disease, comparative pathology and genetically engineered mouse models in oncology, use of human tissues in preclinical drug development (off target profiling, target validation, normal expression profiling), and translational safety. Our popular mouse pathology workshop also returns and provides an excellent opportunity for scientists working with mouse models of disease to learn the fundamentals of murine histology and pathology.

Programme

Note: Programme timings, lecture titles and speakers may be subject to change without notice

THURSDAY 19th NOVEMBER 2026		
08.15 - 08.45	REGISTRATION	
08.45 - 09.00	WELCOME AND INTRODUCTION BY THE PRESIDENT OF THE BSTP – Peter Clements <i>Session Chair: Peter Clements</i>	
09.00 - 09.45	Update on the pathology and pathogenesis of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) <i>Prof. Tim Kendall</i> <i>The University of Edinburgh, UK</i>	
09.45 - 10.30	Translational modelling of human MASLD and leveraging real-world data <i>Prof. Tim Kendall</i> <i>The University of Edinburgh, UK</i>	
10.30 - 11.00	REFRESHMENT BREAK AND POSTER SESSION	
	Session 2: <i>Session Chair: Aleksandra Zalewska</i>	
11.00 - 11.45	"Translational animal models of human kidney disease - fact or folly?" Part 1 <i>Dr. Magnus Söderberg</i> <i>AstraZeneca, Sweden</i>	
11.45 - 12.30	"Translational animal models of human kidney disease - fact or folly?" Part 2 <i>Dr. Magnus Söderberg</i> <i>AstraZeneca, Sweden</i>	
12.30 - 13.30	LUNCH	
13.30 - 14.00	<i>Scientific Organiser of Mouse Pathology Workshop: Dr Ellie Herbert</i> Mouse Necropsy <i>Dr Ellie Herbert</i> <i>Antech Diagnostics, UK</i>	<i>Session Chair: Stephen Drew</i> 13.30 – 14:15 Off-Target Profiling to Enhance Preclinical Assessment of Biologics <i>Dr. Susann Busch</i> <i>AstraZeneca, Sweden</i>
14.00 - 14.30	Neuropathology 101 <i>Dr Deepa B Rao</i> <i>Greenfield Pathology Services, USA</i>	
14.30 - 15.00	Histology Basics <i>Anna MacDonald</i> <i>Labcorp, UK</i>	14:15-15:00 Tissue Cross-Reactivity Studies <i>Paul Edwards</i> <i>Labcorp, UK</i>
15.00 - 15.30	REFRESHMENT BREAK	
15.30 - 16.15	<i>Session Chair: TBC</i> Recognising common background lesions in laboratory mice <i>Liz McInnes</i> <i>Syngenta, UK</i>	<i>Session Chair: Jon Carter</i> Advancing Safer, Targeted Biologics with the Retrogenix® Cell Microarray <i>Dr. Mark Aspinall-O'Dea</i> <i>Retrogenix, Charles River Laboratories, UK</i>
16.15 - 17.00	Investigating unexpected morbidity and mortality in research mice <i>Cheryl Scudamore</i> <i>Exe Pathology, UK</i>	Title: Target Validation and Indication Selection using Human Tissues - Applications and Pitfalls <i>Deon Hildebrand</i>

		GSK, UK
17.00 – 18.00	BSTP Annual General Meeting	
18.00 onwards	Drinks and Canapé Reception	

FRIDAY 20th NOVEMBER 2026	
08.30 - 08.55	REGISTRATION
08.55 - 09.00	INTRODUCTION TO DAY 2 <i>Session Chair: Giovanni Pellegrini</i>
09.00 - 9.45	Characterization of Genetically Engineered Mouse Models (GEMMs) for Nonclinical Safety <i>Dr. Josep Monné</i> <i>Roche, Switzerland</i>
9.45 - 10.30	Unique Challenges underlying Core Concepts in Neuropathology Evaluations <i>Dr. Deepa B Rao</i> <i>Greenfield Pathology Services, USA</i>
10.30 - 11.00	REFRESHMENT BREAK
11.00 - 11.45	Engineered GEMMs for Pharma: Pathology-Driven Models to Power Target Validation and Therapeutic Development <i>Dr. Michelle Porritt</i> <i>AstraZeneca, Sweden</i>
11.45 -12.00	<i>Short talk sponsor</i>
12.00 - 13.00	LUNCH
13.00 - 13.45	<i>Session Chair: Clare Hoover (TBC)</i> In search of the ‘perfect’ model: Mammary tumorigenesis across species. <i>Prof. Kate Hughes</i> <i>University of Cambridge, UK</i>
13.45 - 14.30	Antibody-based therapeutics for targeting the tumour stroma and sarcomas <i>Prof. Clare Isacke</i> <i>The Institute of Cancer Research, UK</i>
14.30 - 15.00	REFRESHMENT BREAK
15.00 - 15.45	Translational research in genetically engineered mouse models of pancreatic cancer <i>Prof. Jen Morton</i> <i>CRUK Scotland Institute/University of Glasgow, UK</i>
15.45 - 16.00	CONCLUDING REMARKS BY THE NEW PRESIDENT OF THE BSTP –